Exagen Inc. (XGN)
| Market Cap | 203.19M |
| Revenue (ttm) | 39.52M |
| Net Income (ttm) | -16.64M |
| Shares Out | 12.64M |
| EPS (ttm) | -72.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $16.06 |
| Previous Close | $16.03 |
| Change ($) | 0.03 |
| Change (%) | 0.19% |
| Day's Open | 16.20 |
| Day's Range | 15.83 - 16.75 |
| Day's Volume | 38,965 |
| 52-Week Range | 10.56 - 23.82 |
SAN DIEGO, Jan. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
Record Testing Revenue, Adopters and AVISE CTD® Volumes
SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
Exagen (XGN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Three currently-undervalued MedTech stocks are flourishing on the back of a few uptrends.
SAN DIEGO, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoim...
Exagen Inc. (XGN) CEO Ron Rocca on Q3 2020 Results - Earnings Call Transcript
Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 83.65% year over year to ($0.34), which beat...
Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing Record Adopters with 99% Stickiness and 14 Million In-Network Lives Added for AVISE® Testing
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
SAN DIEGO, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
SAN DIEGO, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today anno...
Exagen Showcases Six Scientific Presentations at ACR's First Virtual Annual Meeting in November 2020
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced ...
SAN DIEGO, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today anno...
SAN DIEGO, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic aut...
SAN DIEGO, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, is prou...
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...
SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announce...
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...
Exagen Inc. (XGN) CEO Ron Rocca on Q2 2020 Results - Earnings Call Transcript
Testing Experiencing Monthly Sequential Improvement Record Gross Margins of 63%
AVISE Tests Now Available to 6 Million Humana Military Beneficiaries AVISE Tests Now Available to 6 Million Humana Military Beneficiaries
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...
Exagen (XGN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today an...
SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announce...
Exagen Inc. (XGN) CEO Ron Rocca on Q1 2020 Results - Earnings Call Transcript
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2019 Results - Earnings Call Transcript
Exagen Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer, and Anja Kammesheidt, Ph.D.
SAN DIEGO, March 24, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today a...
SAN DIEGO, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
SAN DIEGO, CA, March 09, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic...
About XGN
Exagen develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective ... [Read more...]
| Industry Diagnostics & Research | IPO Date Sep 19, 2019 |
| CEO Fortunato Rocca | Employees 153 |
| Stock Exchange NASDAQ | Ticker Symbol XGN |
Financial Performance
In 2019, Exagen's revenue was $40.39 million, an increase of 24.50% compared to the previous year's $32.44 million. Losses were -$12.04 million, 50.2% more than in 2018.
Analyst Forecasts
According to 5 analysts, the average rating for Exagen stock is "Strong Buy." The 12-month stock price forecast is 24.25, which is an increase of 51.00% from the latest price.